TNFSF10 and cancer: The initial studies which examined the response of the LNCaP and PC3 cell lines to this combination therapy elucidated the fact that this therapy would need to be modified to yield more successful results for cell lines more resistant to TRAIL, yet showed success in ablating a highly metastatic cancer cell line.